Department of Anesthesiology and Intensive Care Medicine, Emergency Medicine and Pain Management, Hospital Dresden-Friedrichstadt; Department of Cardiac Surgery, University Heart Center Dresden, University Hospital, Technische Universität Dresden; Department of Internal Medicine and Cardiology, University Heart Center Dresden, University Hospital, Technische Universität Dresden; Department of Anesthesiology and Intensive Care Medicine, University Hospital, Technische Universität Dresden.
Dtsch Arztebl Int. 2022 Jul 25;119(29-30):514-524. doi: 10.3238/arztebl.m2022.0207.
Acute right heart failure is a life-threatening condition that can arise postoperatively. The options for symptomatic treatment have been markedly expanded in recent years through the introduction of percutaneously implantable mechanical cardiac support systems.
This review is based on publications retrieved by a selective literature search in PubMed as well as on guidelines from Germany and abroad.
The diagnostic evaluation of right heart failure is chiefly based on echocardiography and pulmonary arterial catheteri - zation and is intended to lead to immediate treatment. Alongside treatment of the cause of the condition, supportive management is crucial to patient survival. A variety of ventilation strategies depending on the situation, catecholamine therapies, inhaled selective pulmonary vasodilators, and cardiac support systems are available for this purpose. The in-hospital mortality of postoperative right heart failure is 5-17 %. The results of the use of cardiac support systems reported in case series are dis - appointing, but nonetheless good compared to what these critically ill patients would face without such treatment. In one observational study, the 30-day survival rate was 73.3%.
Survival is aided by the rapid recognition of right heart failure, targeted multidisciplinary treatment, and contact with an extracorporeal life support (ECLS) center for additional supportive treatment measures. Further studies on the use of pharmacological and mechanical cardiac support systems must be carried out to provide stronger evidence on which treatment recommendations can be based.
急性右心衰竭是一种术后危及生命的病症,近年来,通过引入经皮植入式机械心脏支持系统,其治疗方法得到了显著扩展。
本综述基于在 PubMed 中进行的选择性文献检索以及德国和国外的指南中的出版物。
右心衰竭的诊断评估主要基于超声心动图和肺动脉导管检查,并旨在进行即时治疗。除了治疗病症的原因外,支持性管理对患者的生存至关重要。根据具体情况,有多种通气策略、儿茶酚胺治疗、吸入性选择性肺血管扩张剂和心脏支持系统可用于此目的。术后右心衰竭的院内死亡率为 5-17%。在病例系列报告中使用心脏支持系统的结果令人失望,但与这些重症患者在没有此类治疗的情况下所面临的情况相比,结果仍然较好。在一项观察性研究中,30 天生存率为 73.3%。
快速识别右心衰竭、针对性的多学科治疗以及与体外生命支持(ECLS)中心联系以采取额外的支持性治疗措施有助于提高生存率。必须进一步开展关于药物和机械心脏支持系统使用的研究,为治疗建议提供更有力的证据。